DRD2 and schizophrenia: Further supporting a strong dopaminergic basis of PL, patients with schizophrenia given DRD2 blocking typical antipsychotics (e.g., Green et al., 1997; Kern et al., 1998; Kumari et al., 2002), but not atypical antipsychotics (Purdon et al., 2002, 2003; Kumari et al., 2008b), show significant PL impairment.